Moderna, Inc. (MRNA) Downgraded to Market Perform by William Blair

Market Context

Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $207.97 with a market capitalization of $11.6B. The stock has gained 544.4% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow William Blair's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Moderna, Inc.

Among the 10 most recent ratings: 2 Buy, 6 Hold, 2 Sell.

Date	Firm	Rating	Price Target
Oct 27, 2026	William Blair	Market Perform	N/A
Oct 26, 2026	Piper Sandler	Overweight	N/A
Oct 21, 2026	TD Cowen	Hold	N/A
Oct 15, 2026	Goldman Sachs	Neutral	N/A
Oct 07, 2026	Morgan Stanley	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page